Through the application of CRISPR-Cas9 technology, Shimokawa and team revealed that targeting LGR5+ CCSCs for elimination in CRC human organoids results in tumor shrinkage in xenograft models derived from these organoids. This evidence concerns the gene LGR5 and neoplasm.